Levi & Korsinsky Alerts Actinium Pharmaceuticals Investors on Class Action Deadline
In a crucial update for investors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM), the law firm Levi & Korsinsky, LLP has issued a noteworthy reminder regarding an impending lead plaintiff deadline. The firm has filed a class action securities lawsuit targeting the company, alerting affected shareholders to the critical date of May 27, 2025, to request appointment as lead plaintiff.
This significant lawsuit seeks to recover financial losses incurred by investors due to alleged securities fraud, which is said to have persisted from October 31, 2022, through August 2, 2024. During this period, stakeholders may have sustained losses as a result of misleading statements regarding the company’s trials and regulatory submissions made to the FDA concerning its targeted radiotherapy drug, Iomab-B.
Details of the Case
The allegations in the filed complaint indicate that certain defendants inappropriately represented the viability and regulatory standing of Iomab-B, particularly downplaying adverse trial data. They allegedly failed to disclose that the results from the Phase 3 Sierra trial would not meet FDA guidelines necessary for approval. The false disclosures included claims about the drug’s positive outcome trends and the adequacy of additional analyses intended to bolster the company’s application. The defendants' statements are claimed to have misled investors regarding the company's business health, operational prospects, and overall investment potential.
Next Steps for Investors
For shareholders who believe they were disadvantaged during the specified time frame, it is essential to act before the May deadline to secure a position as a lead plaintiff. Participation in the case does not obligate individuals to take on the responsibilities associated with being a lead plaintiff, nor will it incur any costs to join the suit as class members may potentially recuperate losses without bearing out-of-pocket expenses.
Levi & Korsinsky’s Credentials
With a track record spanning over two decades, Levi & Korsinsky has achieved significant victories on behalf of shareholders, recovering hundreds of millions in damages for clients. The team of over 70 legal professionals possesses rich expertise in complex securities litigation, marking the firm as a leading entity in United States securities class action lawsuits. For seven consecutive years, it has been acknowledged in ISS Securities Class Action Services' Top 50 Report for its outstanding performance.
Contact Information
For those seeking further details or wishing to participate in the lawsuit, they may reach out directly to Joseph E. Levi, Esq. at (212) 363-7500 or by email at [email protected]. The firm is located at 33 Whitehall Street, 17th Floor, New York, NY 10004, and provides an online submission form for additional inquiries regarding the lawsuit.
In conclusion, shareholders of Actinium Pharmaceuticals are encouraged to assess their involvement and consider joining this class action to seek eligible compensation. The strategy employed by Levi & Korsinsky emphasizes investor rights and the firm’s commitment to holding entities accountable for securities fraud. Time is of the essence—stakeholders should ensure their claims are voiced before the critical May 27 deadline to maximize their chances of recovery.
This significant lawsuit seeks to recover financial losses incurred by investors due to alleged securities fraud, which is said to have persisted from October 31, 2022, through August 2, 2024. During this period, stakeholders may have sustained losses as a result of misleading statements regarding the company’s trials and regulatory submissions made to the FDA concerning its targeted radiotherapy drug, Iomab-B.
Details of the Case
The allegations in the filed complaint indicate that certain defendants inappropriately represented the viability and regulatory standing of Iomab-B, particularly downplaying adverse trial data. They allegedly failed to disclose that the results from the Phase 3 Sierra trial would not meet FDA guidelines necessary for approval. The false disclosures included claims about the drug’s positive outcome trends and the adequacy of additional analyses intended to bolster the company’s application. The defendants' statements are claimed to have misled investors regarding the company's business health, operational prospects, and overall investment potential.
Next Steps for Investors
For shareholders who believe they were disadvantaged during the specified time frame, it is essential to act before the May deadline to secure a position as a lead plaintiff. Participation in the case does not obligate individuals to take on the responsibilities associated with being a lead plaintiff, nor will it incur any costs to join the suit as class members may potentially recuperate losses without bearing out-of-pocket expenses.
Levi & Korsinsky’s Credentials
With a track record spanning over two decades, Levi & Korsinsky has achieved significant victories on behalf of shareholders, recovering hundreds of millions in damages for clients. The team of over 70 legal professionals possesses rich expertise in complex securities litigation, marking the firm as a leading entity in United States securities class action lawsuits. For seven consecutive years, it has been acknowledged in ISS Securities Class Action Services' Top 50 Report for its outstanding performance.
Contact Information
For those seeking further details or wishing to participate in the lawsuit, they may reach out directly to Joseph E. Levi, Esq. at (212) 363-7500 or by email at [email protected]. The firm is located at 33 Whitehall Street, 17th Floor, New York, NY 10004, and provides an online submission form for additional inquiries regarding the lawsuit.
In conclusion, shareholders of Actinium Pharmaceuticals are encouraged to assess their involvement and consider joining this class action to seek eligible compensation. The strategy employed by Levi & Korsinsky emphasizes investor rights and the firm’s commitment to holding entities accountable for securities fraud. Time is of the essence—stakeholders should ensure their claims are voiced before the critical May 27 deadline to maximize their chances of recovery.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.